Germ cell tumors of the testis

Annals of Surgical Oncology

Volumn 12, Issue 11, 2005, Pages 871-880

  Carver, Brett S ^a   Sheinfeld, Joel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Germ cell tumors; Primary retroperitoneal lymph node dissection; Testicular cancer

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE;

ACUTE LEUKEMIA; AGE DISTRIBUTION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; ECHOGRAPHY; GERM CELL TUMOR; HUMAN; LABORATORY TEST; LUNG DISEASE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; META ANALYSIS; NEPHROTOXICITY; NEUROPATHY; ORCHIECTOMY; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RAYNAUD PHENOMENON; REVIEW; SEMINOMA; SURVIVAL RATE; SURVIVAL TIME; SYMPTOM; SYSTEMATIC REVIEW; TESTIS CANCER; TREATMENT INDICATION;

GERMINOMA; HUMANS; LYMPH NODE EXCISION; MALE; NEOPLASM STAGING; SEMINOMA; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 27144500125     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2005.01.013     Document Type: Review

References (82)

1. American Cancer Society. Cancer Facts and Figures. Atlanta: American Cancer Society, 2005.
2. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J Urol 2003;170:5-11.
3. McKiernan J, Goluboff E, Liberson G, Golden R, Fisch H. Rising risk of testicular cancer by birth cohort in the United States from 1973 to 1995. J Urol 1999;162:361-3.
4. Daniels J, Stutzman R, McLeod D. A comparison of testicular tumors in black and white patients. J Urol 1981;125:341-2.
5. Bosl G, Bajorin D, Sheinfeld J, Motzer R, Chaganti R. Cancer of the testis. In: Devita Y, Hellman S, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott, 2000:1491-518.
6. Moul J, Paulson D, Dodge R, Walther P. Delay in diagnosis and survival in testicular cancer: impact of effective therapy and changes during 18 years. J Urol 1990;143:520-3.
7. Bosl G, Goldman A, Lange P, Vogelzang N, Fraley E, Levitt S. Impact of delay in diagnosis on clinical stage of testicular cancer. Lancet 1981;2:970-3.
8. Moul J, Moellman J. Unnecessary mastectomy for gynecomastia in a testicular cancer patient. Mil Med 1992;157:433-4.
9. Stephenson AJ, Russo P, Kaplinsky R, Sheinfeld J. Impact of unnecessary exploratory laparotomy on the treatment of patients with metastatic germ cell tumor. J Urol 2004;171:1474-7.
10. Bochner BH, Lerner SP, Kawachi M, Williams RD, Scardino PT, Skinner DG. Postradical orchiectomy hemorrhage: should an alteration in staging strategy for testicular cancer be considered? Urology 1995;46:408-11.
11. Capelouto C, Clark P, Ransil B, Loughlin K. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995;153:1397-401.
12. Van der Schyff S Van der , Heidenreich A, Weifbach L. Organ preserving surgery in testicular cancer: long term results (abstract). J Urol 2000;163:645A.
13. Leibovitch I, Foster R, Kopecky K, Donohue J. Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 1995;154:1759-63.
14. Hilton S, Herr H, Teitcher J, Begg C, Castellino R. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 1997;169:521-5.
15. Fleming I, ed. AJCC Cancer Staging Handbook. Philadelphia: Lippincott-Raven, 1998.
16. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancersInternational Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15:594-603.
17. Jamieson J, Dobsin J. Lymphatics of the testicle. Lancet 1910;1:493-95.
18. Skinner D, Leadbetter W. The surgical management of testis tumors. J Urol 1971;106:84-93.
19. Donohue J, Zachary J, Maynard B. Distribution of nodal metastases in nonseminomatous testis cancer. J Urol 1982;128:315-20.
20. Weiscbach L, Boedefeld E. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as a basis for a modified staging lymph node dissection in stage I. J Urol 1987;138:77-82.
21. Sogani P. Evolution of the management of stage I nonseminomatous germ cell tumors of the testis. Urol Clin North Am 1991;18:561-73.
22. Fossa S, Horwich A, Russell J, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. J Clin Oncol 1999;17:1146-54.
23. Fossa S, Aass N, Kaalhus O. Radiotherapy for testicular seminoma stage I. treatment results and long term post irradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989;16:383-8.
24. Dosmann M, Zagars G. Post-orchiectomy radiotherapy for stages I and II testicular seminoma. Int J Radiat Oncol Biol Phys 1993;26:382-90.
25. Willan B, McGowan D. Seminoma of the testis: a 22 year experience with radiotherapy. Int J Radiat Oncol Biol Phys 1985;11:1769-75.
26. Warde P, Gospodarowicz MK, Panzarella T, et al. Stage I testicular seminoma: results of adjuvant irradiation and surveillance. J Clin Oncol 1995;13:2255-62.
27. von der Maase H von der , Specht L, Jacobsen GK, et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur J Cancer 1993;29A:1931-4.
28. Loehrer P, Birch R, Williams S, Greco A, Einhorn L. Chemotherapy of metastatic seminoma: the Southeastern Cancer Study Group experience. J Clin Oncol 1987;5:1212-20.
29. Lashley D, Lowe B. A rational approach to managing stage I nonseminomatous germ cell cancer. Urol Clin North Am 1998;25:405-23.
30. Pohar K, Rabbani F, Bosl G, Motzer R, Bajorin D, Sheinfeld J. Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testis. J Urol 2003;170:1155-8.
31. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855-8.
32. Jewett M, Kong Y, Goldberg S, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988;139:1220-3.
33. Baniel J, Foster R, Rowland R, Bihrle R, Donohue J. Complications of primary retroperitoneal lymph node dissection. J Urol 1994;152:424-7.
34. Hartlapp J, Weissbach L, Bussar-Maatz R. Adjuvant chemotherapy in nonseminomatous testicular tumor stage II. Int J Androl 1987;10:277-84.
35. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? J Clin Oncol 1991;9:1393-6.
36. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): modifications of technique and impact on ejaculation. J Urol 1993;149:237-43.
37. Rabbani F, Sheinfeld J, Mohseni HF, Leon A, Rentzepis MJ, Reuter VE. Low volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001;19:2020-5.
38. Williams SD, Stablein DM, Einhorn LH, et al. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:1433-8.
39. Kondagunta GV, Sheinfeld J. Mazumdar M, et al. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy. J Clin Oncol 2004;22:464-7.
40. Gerber GS, Bissada NK, Hulbert JC, Kavoussi LR, Moore RG, Kantoff PW. Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. J Urol 1994;152:1188-92.
41. Rassweiler JJ, Seemann O, Henkel TO, Stock C, Frede T, Alken P. Laparoscopic retroperitoneal lymph node dissection for nonseminomatous germ cell tumors: indications and limitations. J Urol 1996;156:1108-13.
42. Janetschek G, Hobisch A, Holtl L, Bartsch G. Retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular tumor: laparoscopy versus open surgery and impact of learning curve. J Urol 1996;156:89-93.
43. Nelson JB, Chen RN, Bishoff JT, Oh WK, Kantoff PW, Donehower RC. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999;54:1064-7.
44. LeBlanc E, Caty A, Dargent D, Querleu D, Mazeman E. Extraperitoneal laparoscopic para-aortic lymph node dissection for early stage nonseminomatous germ cell tumors of the testis with introduction of a nerve sparing technique: description and results. J Urol 2001;165:89-92.
45. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003;62:324-7.
46. Steiner H, Peschel R, Janetschek G, Holtl L, Berger AP, Bartsch G. Long-term result of laparoscopic retroperitoneal lymph node dissection: a single-center 10-year experience. Urology 2004;63:550-5.
47. Castillo OA, Urena RD, Pinto IF. Laparoscopic retroperitoneal lymph node dissection for stage I, II NSGCT: 10 years experience (abstract). J Urol 2004;171:933A.
48. Rassweiler JJ, Frede T, Lenz E, Seemann O, Alken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000;37:251-60.
49. Oliver RT, Raja MA, Ong J, Gallagher CJ. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 1992;148:1453-5.
50. Cullen M, Stenning S, Parkinson M. Short course adjuvant chemotherapy in high risk stage I nonseminomatous germ cell tumors of the testis (NSGCTT): an MRC (UK) study report (abstract). Proc Am Soc Clin Oncol 1995;14:244.
51. Studer UE, Burkhard FC, Sonntag RW. Risk adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumor. J Urol 2000;163:1785-7.
52. Meinardi MT, Gietema JA, van der Graaf WTA van der , van Veldhuisen DJ van , Runne MA, Sluiter WJ. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000;18:1725-32.
53. Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21:1513-23.
54. Stephenson AJ, Bosl GJ, Motzer RJ, et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005;23:2781-8.
55. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
56. Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol 1988;6:1031-40.
57. Kaye SB, Mead GM, Fossa S, et al. Intensive inductionsequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998;16:692-701.
58. Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:1683-94.
59. Steyerberg EW, Keizer HJ, Fossa SD, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995;13:1177-87.
60. Aass N, Klepp O, Cavallin-Stahl E, et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9:818-26.
61. Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569-73.
62. Donohue JP, Leviovitch I, Foster RS, Baniel J, Tognoni P. Integration of surgery and systemic therapy: results and principles of integration. Semin Urol Oncol 1998;16:65-71.
63. Einhorn LH. Testicular cancer as a model for a curable neoplasm: the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1981;41:3275-80.
64. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993;11:1294-9.
65. Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group. J Clin Oncol 2001;19:2647-57.
66. Donohue JP, Rowland RG, Kopecky K, et al. Correlation of computerized tomographic changes and histological findings in 80 patients having radical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176-9.
67. Debono DJ, Heilman DK, Einhorn LH, Donohue JP. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous germ cell tumors. J Clin Oncol 1997;15:1455-64.
68. Fossa SD, Ous S, Lien HH, Stenwig AE. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989;141:557-9.
69. Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998;159:133-8.
70. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
71. Baniel J, Foster RS, Einhorn LH, Donohue JP. Late relapse of clinical stage I testicular cancer. J Urol 1995;154:1370-2.
72. Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumor who fail to normalize serum tumor markers after chemotherapy. Urology 1994;43:74-80.
73. Murphy BR, Breeden ES, Donohue JP, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993;11:324-9.
74. Beck SD, Patel MI, Sheinfeld J. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. J Urol 2004;171:168-71.
75. Herr HW, Sheinfeld J, Puc HS, et al. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997:157:860-2.
76. 18Fluorodeoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034-9.
77. Moshorafa AA, Foster RS, Koch MO. Complications of post-chemotherapy retroperitoneal lymph node dissection (abstract). J Urol 2003;169:930A.
78. Patel MI, Beck S, Bosl GJ, Sheinfeld J. Histology of good risk nonseminomatous germ cell tumor (NSGCT) patients following retroperitoneal lymph node dissection (PC-RPLND) after 4 cycles of etoposide and cisplatin (EPx4) (abstract). J Urol 2003;169:681A.
79. See WA, Laurenzo JF, Dreicer R, Hoffman HT. Incidence and management of testicular carcinoma metastatic to the neck. J Urol 1996;55:590-2.
80. Tiffany P, Morse MJ, Bosl G, et al. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 1986;57:978-83.
81. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Thoracotomy for postchemotherapy resection of pulmonary residual tumor mass in patients with nonseminomatous testicular germ cell tumors: aggressive surgical resection is justified. Chest 1997;112:967-73.
82. Brenner PC, Herr HW, Morse MJ, et al. Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol 1996;14:1765-9.